STRO-1+ Cells Restore Pancreatic Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type I and type II diabetes are limited in effectively addressing pancreatic dysfunction, with existing therapies either replacing insulin or managing symptoms rather than correcting pancreatic damage, and they often come with significant side effects and limitations such as short half-life, frequent administration, and limited potency.
Innovation Solution
Administration of STRO-1+ cells, which are mesenchymal precursor cells, to promote pancreatic regeneration, increase insulin production, and improve pancreatic function by inducing the production of new beta cells and microvessels, thereby addressing the underlying pancreatic dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diabetes treatments (insulin replacement or symptom management) are used, then blood glucose levels can be controlled, but they do not address the underlying pancreatic damage and require frequent administration with significant side effects
Solution Approach 1:
The patent applies preliminary action by administering STRO-1+ cells before significant pancreatic damage occurs or early in the disease progression. These cells are intended to regenerate beta cells and prevent further pancreatic dysfunction, addressing the root cause rather than just managing symptoms that develop later. This proactive approach reduces the need for frequent insulin administrations and complex treatment regimens.
Solution Approach 2:
The STRO-1+ cells serve as an intermediary between the administered therapy and the pancreatic tissue. These mesenchymal precursor cells differentiate into beta cells and secrete factors that promote regeneration and protect existing pancreatic cells. This intermediary mechanism translates the treatment into direct pancreatic repair, reducing reliance on external insulin replacement and complex symptom management protocols.
2Productivity
If insulin replacement therapy is used, then blood glucose control is achieved, but it does not restore pancreatic function and requires frequent administration
Solution Approach 1:
The patent implements self-service by enabling the pancreas to produce its own insulin through STRO-1+ cell differentiation into functional beta cells. These regenerated beta cells autonomously sense blood glucose levels and secrete insulin as needed, restoring the pancreas's natural insulin production capability. This eliminates or reduces the need for external insulin administration and frequent monitoring, allowing the system to self-regulate glucose homeostasis.
3Reliability
If existing therapies are used, then symptoms are managed, but pancreatic damage progresses and function is not restored
Solution Approach 1:
The patent converts the harmful progression of pancreatic damage into a beneficial regenerative process. STRO-1+ cells not only replace lost beta cells but also secrete paracrine factors that protect remaining pancreatic tissue from further damage, reduce inflammation, and promote overall pancreatic regeneration. This transforms the trajectory from progressive damage to active repair and functional restoration.
Solution Approach 2:
STRO-1+ cells act as intermediary agents that mediate between the administered therapy and the damaged pancreatic tissue. These cells differentiate into beta cells to restore insulin production while simultaneously secreting protective factors that prevent further damage to the pancreatic parenchyma. This dual mechanism addresses both the loss of function and the progression of damage simultaneously.
Data Source
AI summary
The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.